Article thumbnail

Ceftaroline in complicated skin and skin-structure infections

By Paul O Hernandez, Sergio Lema, Stephen K Tyring and Natalia Mendoza

Abstract

Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recommended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA and other multidrug-resistant strains, warrants its consideration as a first-line treatment option for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to further elucidate its role in the treatment of cSSSIs

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3269128
Provided by: PubMed Central

Suggested articles

Citations

  1. A practical guide to the treatment of complicated skin and soft tissue infections.
  2. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis.
  3. (2008). A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects [abstract no A-1888].
  4. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia.
  5. (2011). Alternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
  6. Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline. Ther Clin Risk Manag.
  7. (2008). Antibiotic options for treating communityacquired MRSA. Expert Rev Anti Infect Ther.
  8. Antibiotics for Gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftaroline.
  9. (2008). Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother.
  10. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
  11. (2005). Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt).
  12. (2011). Antimicrobial ointments and methicillin-resistant Staphylococcus aureus USA300. Emerg Infect Dis.
  13. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008).
  14. Antimicrobial susceptibility of Grampositive cocci isolated from skin and skin-structure infections in European medical centres.
  15. (2010). CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother.
  16. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
  17. (2011). CDC.gov [homepage on the Internet]. Atlanta: MRSA Infections. [Updated
  18. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother. 2010;65 Suppl 4:iv17–iv31.
  19. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram- positive activity.
  20. Ceftaroline: a comprehensive update.
  21. Ceftaroline: a new broad-spectrum cephalosporin.
  22. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.
  23. Ceftaroline: a novel broadspectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
  24. (2011). Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis.
  25. (2008). Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol.
  26. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis.
  27. (2011). Community prevalence of methicillin and vancomycin resistant Staphylococcus aureus in and around Bangalore, southern India. Rev Soc Bras Med Trop.
  28. (2011). Comparison of communityassociated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007–2009 study. Diagn Microbiol Infect Dis.
  29. (2004). Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother.
  30. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt). 2008;9 Suppl 1:s17–s27.
  31. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infections.
  32. (2002). Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis.
  33. (2010). FDA.gov [homepage on the Internet]. Maryland: Guidance for industry: Acute bacterial skin and skin structure infections: developing drugs for treatment; [cited Aug
  34. (1998). FDA.gov [homepage on the Internet]. Maryland: Guidance for industry: Uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment; [cited
  35. (2010). FDA.gov [homepage on the internet]. Maryland: Teflaro label and approval history. [Updated daily, cited
  36. Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus.
  37. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin Infect Dis. 2002;35 Suppl 1:S119–S125.
  38. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
  39. (2009). In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother.
  40. (2008). In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother.
  41. (2009). In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother.
  42. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother.
  43. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
  44. (2008). In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother.
  45. (2011). Increasing role of Staphylococcus aureus and community-acquired methicillinresistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansion. Microb Drug Resist.
  46. (1992). Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from
  47. (2011). Institutional perspective on the impact of positive blood cultures on the economic and clinical outcomes of patients with complicated skin and skin structure infections: Focus on Gram-positive infections. Clin Ther.
  48. (2010). Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis.
  49. (2010). Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother.
  50. (2008). Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother.
  51. (2008). Medical Microbiology and Immunology. 10th ed.
  52. Methicillin-resistant S. aureus infections among patients in the emergency department.
  53. (2009). Methicillinresistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg Infect Dis.
  54. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents. 2009;34 Suppl 1:S24–S29.
  55. (2011). New Drug Bulletin: Ceftaroline Fosamil (TeflaroTM-Forest Pharmaceuticals). Salt Lake City: University of Utah Hospitals and Clinics;
  56. Newer treatment options for skin and soft tissue infections.
  57. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved antimethicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother. 2010;65 Suppl 4:iv33–iv39.
  58. (2006). Pharmacokinetics (PK) of ceftaroline (PPI0903) in subjects with mild or moderate renal impairment (RI) [abstract no A-1939].
  59. (2007). Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother.
  60. Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole. Ther Clin Risk Manag.
  61. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother.
  62. (2011). Teflaro.com [homepage on the Internet]. St Louis: Teflaro: proven effective in acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Highlights of prescribing information.
  63. (2009). The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis.
  64. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis.
  65. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
  66. (2010). The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother.
  67. (2004). The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis.
  68. The safety record of fusidic acid in non-US markets: a focus on skin infections. Clin Infect Dis.
  69. The treatment triangle for staphylococcal infections.
  70. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
  71. (2006). Trends in the occurrence of MRSA strains in Upper Austria from
  72. (2011). Tygacil [homepage on the Internet]. New York: Expanded broadspecrum IV antibiotic indicated for adults with cSSSI, cIAI, and CABP due to the indicated pathogens. Available from: http://www.pfizerpro. com/hcp/tygacil/indications/cSSSI. Accessed
  73. (2010). Tyring SK. Emerging drugs for complicated skin and skinstructure infections. Expert Opin Emerg Drugs.
  74. Update of antimicrobial resistance in Gram-positive microorganisms.
  75. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.